Xilio Therapeutics Files 2024 10-K
Ticker: XLO · Form: 10-K · Filed: Mar 11, 2025 · CIK: 1840233
Sentiment: neutral
Topics: 10-K, pharmaceuticals, financing, SEC filing
Related Tickers: GILD
TL;DR
Xilio's 2024 10-K is in. Check out financing deals and Gilead stock purchase.
AI Summary
Xilio Therapeutics, Inc. filed its 2024 10-K on March 11, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company, based in Waltham, MA, is involved in the pharmaceutical preparations industry. Key events during the reporting period and subsequent to year-end include various financing activities and agreements, such as the Private Placement Gilead Stock Purchase Agreement and the Leerink Sales Agreement.
Why It Matters
This filing provides investors with a comprehensive overview of Xilio Therapeutics' financial health, operational activities, and strategic developments for the fiscal year 2024, including significant agreements and financing events.
Risk Assessment
Risk Level: medium — As a company in the pharmaceutical preparations industry, Xilio Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2024 — Fiscal Year End (Reporting period for the 10-K)
- 2025-03-11 — Filing Date (Date the 10-K was submitted to the SEC)
Key Players & Entities
- Xilio Therapeutics, Inc. (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- 2025-03-11 (date) — Filing date
- Waltham, MA (location) — Company headquarters
- Gilead (company) — Participant in stock purchase agreement
- Leerink (company) — Participant in sales agreement
FAQ
What is the primary business of Xilio Therapeutics, Inc.?
Xilio Therapeutics, Inc. is primarily involved in the Pharmaceutical Preparations industry, as indicated by its SIC code [2834].
When did Xilio Therapeutics, Inc. file its 2024 10-K?
Xilio Therapeutics, Inc. filed its 2024 10-K on March 11, 2025.
Where is Xilio Therapeutics, Inc. headquartered?
Xilio Therapeutics, Inc. is headquartered in Waltham, MA.
What significant agreements are mentioned in relation to the fiscal year 2024?
The filing mentions the Private Placement Gilead Stock Purchase Agreement and the Leerink Sales Agreement, among others.
What is the SEC file number for Xilio Therapeutics, Inc.'s filings?
The SEC file number for Xilio Therapeutics, Inc. is 001-40925.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 11, 2025 regarding Xilio Therapeutics, Inc. (XLO).